CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
M2025-222-01
Phase 2 small_molecule active
Quick answer
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) is a Phase 2 program (small_molecule) at Daihong Liu with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daihong Liu
- Indication
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active